dc.description.sponsorship | This work was supported by the German Federal Ministry of Education and Research (BMBF) within the
framework of the e:Med research and funding concept (grant 01ZX1313A-2014). The ADVANCE study was
supported by a grant from the Reynold's Foundation and NHLBI grant HL087647. Sample collection in the
Cardiogenics Consortium (http://www.cardiogenics.eu/web/) was funded by the 6th Framework Program of the
European Union (LSHM-CT-2006-037593). We thank all the participants and clinicians involved in the
recruitment process at Cambridge and Leicester (UK), Luebeck and Regensburg (Germany), and Paris (France).
CATHGEN was supported by NIH grants HL095987 and HL101621. The Cleveland Clinic Gene Bank study was
funded by P01HL076491 (to S.L.H). EGCUT was supported by Estonian Research Council grant no. IUT20-60
and Research Roadmap grant no. 3.2.0304.11-0312 and by University Tartu grant no. ARENG SP1GV. The
FGENTCARD-Functional Genomic diagnostic tools for coronary artery disease project was funded by an EU
FP6 award. We thank the patients for agreeing to participate in the study. We thank Sonia Youhanna, Nour
Moukalled and Bariaa Khalil for their help with subject recruitment and data collection. The work of FINCAVAS
was supported by the Competitive Research Funding of the Tampere University Hospital (Grant 9M048 and
9N035), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil
Aaltonen Foundation, Finland, and the Tampere Tuberculosis Foundation. The authors thank the staff of the
Department of Clinical Physiology for collecting the exercise test data. The GerMIFS studies were supported by
grants from the German Federal Ministry of Education and Research (BMBF) within the framework of NGFN
and NGFN-plus (Atherogenomics) and e:Med research and funding concept (e:AtheroSysMed, grant
01ZX1313A-2014), the Fondation Leducq (CADgenomics: Understanding CAD Genes, 12CVD02), and the
European Union Sixth Framework Programme FP6 (under grant agreement FP6-LIFESCIHEALTH
(Cardiogenics)) and the Seventh Framework Programme FP7/2007-2013 under grant agreement n°
HEALTH-F2-2013-601456 (CVgenes-at-target). The Heart Protection Study (HPS) (ISRCTN48489393) was
supported by the UK Medical Research Council (MRC), British Heart Foundation, Merck and Co (manufacturers
of simvastatin), and Roche Vitamins Ltd (manufacturers of vitamins). Genotyping was supported by a grant to
Oxford University and CNG from Merck and Co. Jemma C. Hopewell acknowledges support from the British
Heart Foundation (FS/14/55/30806). HPS acknowledges the National Blood Service (NBS) donors and UK Twin
study for using as population controls. A full list of the investigators who contributed to the generation of the NBS
data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under
award 07611. The UK Twin study was funded by the Wellcome Trust; European Community‟s Seventh
Framework Programme (FP7/2007–2013). The Helsinki Sudden Death Study (HSDS) was financially supported
by EU’s 7th Framework Programme (grant no. 201668 for AtheroRemo), the Tampere University Foundation, the
Tampere University Hospital Medical Funds (grants X51001, 9M048 and 9N035 for Terho Lehtimäki, the Emil
Aaltonen Foundation (Terho Lehtimäki, the Finnish Foundation of Cardiovascular Research (Terho Lehtimäki,
Pekka J. Karhunen), the Pirkanmaa Regional Fund of the Finnish Cultural Foundation, the Yrjö Jahnsson
Foundation, and the Tampere Tuberculosis Foundation (Terho Lehtimäki). LIFE-Heart is a part of the LIFE –
Leipzig Research Center for Civilization Diseases, Universität Leipzig. LIFE is funded by means of the European
Union, by the European Regional Development Fund (ERDF) and by means of the Free State of Saxony within the
framework of the excellence initiative. The LOLIPOP study is supported by the National Institute for Health
Research (NIHR) Comprehensive Biomedical Research Centre Imperial College Healthcare NHS Trust, the
British Heart Foundation (SP/04/002), the Medical Research Council (G0601966, G0700931), the Wellcome
Trust (084723/Z/08/Z), the NIHR (RP-PG-0407-10371), European Union FP7 (EpiMigrant, 279143) and Action
on Hearing (G51). We thank the participants and research staff who made the study possible. LURIC was
supported by the 7th Framework Program (integrated project AtheroRemo, grant agreement number 201668 and
RiskyCAD, grant agreement number 305739) of the European Union and by the INTERREG IV Oberrhein
Program (Project A28, Genetic mechanisms of cardiovascular diseases) with support from the European Regional
Development Fund (ERDF) and the Wissenschaftsoffensive TMO. We extend our appreciation to the participants
of the LURIC study and thank the LURIC study team who were either temporarily or permanently involved in
patient recruitment as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen
General Hospital and the Universities of Freiburg and Ulm, Germany. The MIGen study was funded by
R01HL087676 from the US National Heart, Lung, and Blood Institute. The Mount Sinai IPM Biobank Program is
supported by The Andrea and Charles Bronfman Philanthropies. It was in part supported by NHGRI
U01HG007417. OHGS_A2, OHGS_B2, and OHGS_C2 were funded by Canadian Institutes of Health Research
(# MOP-2380941 to R.M.), (#MOP82810, MOP77682 to R.R., A.F.S. & R.M.); Canada Foundation for Innovation
(#11966 to R.R., R.M. & A.F.S.; Heart & Stroke Foundation of Canada (#NA6001, #NA6650 to R.M). PIVUS was
supported by Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellow), European Research Council
(ERC Starting Grant), Swedish Diabetes Foundation (grant no. 2013-024), Swedish Research Council (grant no.
2012-1397), and Swedish Heart-Lung Foundation (20120197). We thank the SNP&SEQ Technology Platform in
Uppsala (www.genotyping.se) for excellent genotyping. The computations were performed on resources provided
by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under
Project b2011036. PROCARDIS was supported by the European Community Sixth Framework Program
(LSHM-CT- 2007-037273), AstraZeneca, the British Heart Foundation, the Swedish Research Council, the Knut
and Alice Wallenberg Foundation, the Swedish Heart-Lung Foundation, the Torsten and Ragnar Söderberg
Foundation, the Strategic Cardiovascular Program of Karolinska Institutet and Stockholm County Council, the
Foundation for Strategic Research and the Stockholm County Council (560283). Research in SDS was partly
supported by NIH grants -R01DK082766 funded by the National Institute of Diabetes and Digestive and Kidney
Diseases and NOT-HG-11-009 funded by National Genome Research Institute, and VPR Bridge grant from
University of Oklahoma Health Sciences Center, Oklahoma City, USA. Recruitment for THISEAS was partially
funded by a research grant (PENED 2003) from the Greek General Secretary of Research and Technology; we thank all the dieticians and clinicians for their contribution to the project. TwinGene was supported by grants
from the Ministry for Higher Education, the Swedish Research Council (M-2005-1112 and 2009-2298),
GenomEUtwin (EU/QLRT-2001-01254; QLG2-CT-2002-01254), NIH grant DK U01-066134, Knut and Alice
Wallenberg Foundation (Wallenberg Academy Fellow), European Research Council (ERC Starting Grant),
Swedish Diabetes Foundation (grant no. 2013-024), Swedish Research Council (grant no. 2012-1397), and
Swedish Heart-Lung Foundation (20120197). We thank the SNP&SEQ Technology Platform in Uppsala (www.
genotyping.se) for excellent genotyping. The computations were performed on resources provided by SNIC
through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project
b2011036. ULSAM was supported by Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellow),
European Research Council (ERC Starting Grant), Swedish Diabetes Foundation (grant no. 2013-024), Swedish
Research Council (grant no. 2012-1397), and Swedish Heart-Lung Foundation (20120197). We thank the
SNP&SEQ Technology Platform in Uppsala (www.genotyping.se) for excellent genotyping. The computations
were performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced
Computational Science (UPPMAX) under Project b2011036. Recruitment for the WTCCC study was funded by
the British Heart Foundation and genotyping by the Wellcome Trust. Themistocles L. Assimes was supported by
an NIDDK career development award DK088942. Panos Deloukas’s work forms part of the research themes
contributing to the translational research portfolio of Barts Cardiovascular Biomedical Research Unit which is
supported and funded by the National Institute for Health Research. Analysis was partly supported by BHF grant
(to Panos Deloukas) RG/14/5/30893. Martin Farrall and Hugh Watkins acknowledge the support of the Wellcome
Trust core award (090532/Z/09/Z) and Martin Farrall, Hugh Watkins and Theodosios Kyriakou, the BHF Centre
of Research Excellence. Anuj Goel, Hugh Watkins and Theodosios Kyriakou acknowledge European Union
Seventh Framework Programme FP7/2007-2013 under grant agreement no. HEALTH-F2-2013-601456
(CVGenes@Target) & and Anuj Goel, the Wellcome Trust Institutional strategic support fund. The UK Twin
study was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007-
2013). PoBI samples from the Wellcome Trust funded People of the British Isles project. Sekar Kathiresan
is supported by the Donovan Family Foundation, Fondation Leducq, MGH Research Scholar Award, and R01
HL107816. Andrew P. Morris is a Wellcome Trust Senior Fellow in Basic Biomedical Science, funded under grant
WT098017. Christopher P. Nelson and Nilesh J. Samani are funded by the British Heart Foundation and Nilesh J.
Samani is a UK NIUHR Senior Investigator. Christopher P. Nelson and Nilesh J. Samani are funded by the British
Heart Foundation and Nilesh J. Samani is a UK NIUHR Senior Investigator. Samuli Ripatti was supported by the
Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No. 213506 and 129680), Academy
of Finland (Grant No. 251217 and 285380), the Finnish foundation for Cardiovascular Research, the Sigrid
Juselius Foundation and the European Community’s Seventh Framework Programme (FP7/2007-2013) through
the BioSHaRE-EU (Biobank Standardisation and Harmonisation for Research Excellence in the European Union)
project, grant agreement 261433. Alexandre F. R. Stewart is supported by operating grants from the Canadian
Institute of Health Research and Natural Sciences and Engineering Research Council of Canada. Hong-Hee Won
is supported by a postdoctoral award from the American Heart Association (15POST23280019). | en_US |